Compare MNY & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNY | JSPR |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.7M | 68.4M |
| IPO Year | N/A | N/A |
| Metric | MNY | JSPR |
|---|---|---|
| Price | $1.32 | $1.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $4.00 | ★ $25.60 |
| AVG Volume (30 Days) | 62.4K | ★ 3.3M |
| Earning Date | 12-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $68,998,322.00 | N/A |
| Revenue This Year | $15.76 | N/A |
| Revenue Next Year | $20.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $1.56 |
| 52 Week High | $2.40 | $26.05 |
| Indicator | MNY | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 49.05 | 30.58 |
| Support Level | $1.28 | $1.68 |
| Resistance Level | $1.37 | $2.42 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 44.44 | 2.56 |
MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services. Geographically it operates in Singapore, Hong Kong, Taiwan, Malaysia and the Philippines.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.